Abstracts

42 – Weight Gain in People With HIV

People with HIV (PWH) are facing multiple challenges in the battle against weight gain, including the growing, worldwide obesity epidemic and its drivers, normal aging and HIV- and antiretroviral therapy (ART)-associated contributors. The worldwide obesity epidemic is beyond the scope of this talk but must be considered when assessing individual patient risk and treatment options.…

16 – HIV Cure: A Translational Research Perspective

Antiretroviral therapy (ART) has transformed HIV-1 infection from a fatal disease into a manageable chronic condition. However, longitudinal studies reveal that the decay rate of the HIV-1 reservoir is so slow that ART alone cannot eliminate the reservoir within the lifetime of people living with HIV-1 (PLWH). This underscores the urgent need for safe and…

41 – Long COVID: Causes, Consequences, and the Way Forward

Long Covid is a disabling post-viral disease state that impacts over 400 million people worldwide, with no effective treatment currently available. Despite incomplete mechanistic understanding, lack of clinically actionable biomarkers, and insufficient policymaker recognition, significant progress has been made in recent years, revealing a clear histological and pathophysiological basis for the condition. SARS-CoV-2 infection prompts…

39 – Complexities of HIV Diagnosis: What Lies Beneath

Is testing the key to unlocking PrEP scale-up? The use of antiretroviral drugs (ARVs) to prevent new HIV infections has been well-established for decades, particularly in the context of pre-exposure prophylaxis (PrEP). Yet, only an estimated 2.5 million people are currently using PrEP—far fewer than the 10 million needed to meet global HIV prevention goals…

34 – Clinical Management of Women With HIV in Menopause

Menopause represents a highly vulnerable time for women physically, mentally, and socially. The growing body of menopause research among women living with HIV (WLWH) demonstrates that this vulnerable population experiences greater mood and vasomotor symptom burden, which adversely impacts adherence to clinic visits and antiretroviral therapy. Estrogen loss associated with menopause may further enhance the…

22 – HIV Care Continuum in Children

Children aged 0-15 years lag behind adults in achieving HIV treatment goals across HIV testing, initiation of antiretroviral therapy and viral suppression. While early diagnosis of pediatric HIV has scaled up significantly, children continue to slip through the cracks and remain undiagnosed and untreated. For children living with HIV, challenges in adherence to treatment is…

51 – We’ll Come to You: A Mobile Clinic Preexposure Prophylaxis Delivery Model

Effective HIV prevention requires well-designed and well-targeted services tailored according to client characteristics and needs. PrEP biomedical product choice allows young people to select a formulation that works for them and their lifestyle, while HIV prevention impact may be even greater if PrEP service delivery models also match young people’s diverse lifestyles and unique needs.…

19 – Cellular and Tissue Sources of Viral Persistence and Rebound

Cellular and tissue sources of viral rebound primarily originate from long-lived reservoirs of HIV in individuals under antiretroviral therapy (ART). Key cellular reservoirs include CD4+ T cells, particularly memory subsets like central memory (Tcm), which harbor latent provirus. Tissue-specific sources include lymphoid tissues (lymph nodes, spleen, and gut-associated lymphoid tissue), where virus can persist despite…